



Since its founding in 1964, ASCO has cultivated a substantial global membership network that includes more than 50,000 cancer clinicians. At Conquer Cancer<sup>®</sup>, the ASCO Foundation, we're committed to leveraging that network to raise funds in support of ASCO's mission and to make an impact on every cancer, every patient, everywhere.

By applying the latest research innovations and evidence-based practices in the field, our physician network touches the lives of every oncology patient around the world. Bolstered by their expertise and experience, ASCO and Conquer Cancer are committed to promoting high-quality care for every patient facing cancer. CancerLinQ is an extension of ASCO's long-standing and widely accepted quality improvement efforts.


## 2023 UPDATE

### EXECUTIVE SUMMARY

CancerLinQ®, a subsidiary of ASCO, is a mission-driven, health technology company that aims to improve quality of care and health outcomes for all patients with cancer, while also advancing evidence-based research. By empowering oncologists through the power of data analytics — and by advancing precision oncology — CancerLinQ is committed to revolutionizing how cancer is managed and to achieving better results for oncology patients around the world.

#### CancerLinQ BY THE NUMBERS

CancerLinQ has One of the Broadest and Most Diverse Networks in Oncology




For CancerLinQ, 2023 has been a year of change, with more opportunities opening within CancerLinQ Discovery® and the potential for partnerships to expand the group's reach and capabilities. The development team is constantly improving the technologies, while the product team carefully monitors the requests and needs of CancerLinQ practices. We are particularly proud of CancerLinQ for accomplishing so much with a lean team of employees.

### NETWORK GROWTH AND PRACTICE ACTIVATIONS

The CancerLinQ network has grown in 2023. One new health organization has joined the network; also, one new parent organization of a current CancerLinQ practice has signed with CancerLinQ. At least three additional practices are expected to sign before the end of the year. The Account Management team has worked hard to expand the CancerLinQ network, and leadership plans to incorporate a sales professional who can increase those numbers even more.

In 2023 alone, five practices have completed activation, with three more in progress during Q3. Three additional practices are currently planning for activation, and the team is on track to meet its goal of 12 total activations in 2023.







## DATA AND INFORMATICS IMPROVEMENTS

CancerLinQ set a goal this year to improve how it captures regulatory-grade, real-world data for every patient with cancer. This is core to delivering data-driven insights that revolutionize clinical research and care delivery — a critical aspect of CancerLinQ's mission. Determined to bring the benefits of precision oncology to every patient in need, CancerLinQ has sought to improve the relevance and reliability of its data through some key initiatives.

CancerLinQ has focused on increasing the scope of its database, both in terms of actively managed cases that are eligible for clinical decision support solutions and in terms of overall patient counts. This approach maximizes the impact of CancerLinQ's products and solutions, placing them on track for a 10-percent increase over last year.

CancerLinQ has also invested in improving the reliability of the data it aggregates through Project Oncuality (oncology + quality), which allows them to measure the quality of their data according to industry standard best practices. This represents a major advancement in understanding and improving the quality of the data CancerLinQ manages, ensuring it reflects the care delivered as accurately as possible.

By adopting next-generation sequencing in routine clinical care and by developing standards for data exchange, CancerLinQ sees an opportunity to evolve its solutions to reflect innovations in precision medicine by integrating with new sources of genomic data. Already, CancerLinQ has completed one proof of concept, and they have plans to launch an additional pilot integration this year. Also, by auditing existing data connections, CancerLinQ has discovered a wealth of genomic information they can utilize to benefit SmartLinQ® and CancerLinQ Discovery through the end of the year.


CancerLinQ is leveraging advances in artificial intelligence by piloting novel solutions for natural language processing and charting abstraction techniques to unlock the value of the medical text aggregated from contributing EHR systems. This significantly improves the overall data quality by addressing missing data elements that are key to understanding the healthcare experience of patients with cancer. CancerLinQ hopes to complete these projects and to introduce these new approaches in a scalable manner across the CancerLinQ network by the end of the year.


## PRODUCT UPDATES

SmartLinQ, CancerLinQ's practice-facing solution, has recently experienced significant updates. It's been redesigned as an app store experience, providing network practices with access to a variety of tools, all intended to address the complexities of cancer treatment. It offers the type of features that practices have come to expect from CancerLinQ, along with a growing set of curated and customized solutions from CancerLinQ collaborators. Together, these tools address some of the pain points of operating an oncology practice and treating patients with cancer. One such tool is the new Biosimilars Dashboard, which gives practices a way to track utilization and cost-savings goals by displaying usage of biosimilar drugs.

Many CancerLinQ practices also participate in ASCO's Quality Oncology Practice Initiative (QOPI®) Certification program, for which CancerLinQ has an automated pathway for chart abstraction and submission. This year, the QOPI Certification Program Pathway was redesigned to allow practices to see where exactly they are in their QOPI Certification journey: from submission for "Initial Certification" to maintenance rounds and through recertification. A timeline highlights associated due dates with each milestone. Also new this year, at the request of practices, is a "preview" of the next measure performance period, which allows practices to pivot and focus on specific measures that might affect their QCP score and certification.

While SmartLinQ features have primarily focused on quality improvement in the past, CancerLinQ is moving toward launching provider-facing, precision oncology support features toward the end of 2023. The team has held numerous rounds of user interviews with providers and staff members in the CancerLinQ network






to understand where a gap exists in precision oncology workflows and how CancerLinQ could support these providers. At front and center, practices have communicated a need for tools to help identify patients for newly approved, biomarker-targeted therapies and to identify patients who qualify for somatic molecular testing.

During the second half of 2023, the CancerLinQ team is developing the first of these features: a tool that helps providers identify patients who match to the FDA label of a newly approved or expanded biomarker-targeted therapy. This feature is on track to launch early in the fourth quarter, and the team is excited to expand the offering into more provider workflows.

CancerLinQ Discovery® provides access to comprehensive, de-identified, real-world oncology data that reflects the longitudinal cancer care experiences of patients with the full range of malignant neoplasms, both solid tumors and hematologic malignancies. This rich and diverse database provides the research and technology community with access to data for a variety of real-world research use cases and for artificial intelligence and machine learning model

development. This year, the CancerLinQ Discovery database grew to include more than 6.7 million total patient records and continues to reflect the diversity of patient care with data from patients across all oncology care settings and from all 50 U.S. states. In 2023, CancerLinQ has been able to offer CancerLinQ Discovery® to a wider audience of researchers, allowing them to generate real-world evidence and insights that will help shape the future of cancer care.



## RESEARCH REPORTS

CancerLinQ data has been used by researchers to publish 24 abstracts and manuscripts. Most of these were presented at the 2023 ASCO Annual Meeting, and they are featured in the Scientific Evidence Guide, available on CancerLinQ's [website](#). These include studies of the tumor characteristics and treatment outcomes for patients with lung cancer, breast cancer, bladder cancer, gynecologic malignancies, and multiple myeloma, among others.

**Some of the novel and diverse topics covered include:**

- Using generative artificial intelligence to identify patients for trials.
- Developing machine learning models to predict the risk of brain metastases for patients with early-stage, non-small-cell lung cancer.
- Identifying clinical predictors for shortened survival in patients experiencing severe adverse events following immunotherapy.
- Characterizing real-world outcomes in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecanhziy.



## IN CLOSING

Since its launch in 2014, CancerLinQ, ASCO and Conquer Cancer have made tremendous strides towards providing the highest quality patient care. Together, we envision a new paradigm, one in which knowledge conquers cancer and all people with cancer have equitable access to quality care. We're committed to providing products and services that reflect a deep understanding of today's oncologists, cancer centers, researchers, and the patients they're determined to help.

CancerLinQ enables the sharing of vital information that empowers patients and providers. As a trusted partner to more than 100 cancer centers and community oncology practices, CancerLinQ is uniquely positioned to advance cancer care and research. We are excited to uncover and cultivate new opportunities to continue improving cancer care delivery by empowering oncology care teams to learn from patients throughout their care and to advance clinical research in a way that accurately reflects the diversity of today's oncology patients. Thanks to generous supporters like yourselves, we remain confident that we will achieve that.




**CONQUER**  
**CANCER®**  
THE ASCO FOUNDATION




## RECOGNITION

As a generous donor of CancerLinQ, you continue to be recognized in various ways. Some recent examples are noted below.



Major donors recognized in front of the CancerLinQ booth at the 2023 ASCO Annual Meeting.



Recognition of CancerLinQ donors on the video wall at the 2023 ASCO Annual Meeting.



CancerLinQ donors were also provided special recognition at their organization's booth in the Exhibit Hall at the 2023 ASCO Annual Meeting. Some of our donors are featured on the next page.





AstraZeneca recognized as a CancerLinQ supporter in their booth at the 2023 ASCO Annual Meeting.




Novartis Oncology recognized as a CancerLinQ supporter in their booth at the 2023 ASCO Annual Meeting.



Amgen recognized as a CancerLinQ supporter in their booth at the 2023 ASCO Annual Meeting.



Lilly recognized as a CancerLinQ supporter in their booth at the 2023 ASCO Annual Meeting.



Genentech BioOncology™ recognized as a CancerLinQ supporter in their booth at the 2023 ASCO Annual Meeting.